Survodutide · Research brief

BI 456906 Same as Survodutide? (Dual Agonist Explained)

Real Peptides Research TeamEditorial

Updated April 9, 20267 min read

60 WORDS

Short answer

Key takeaways

BI 456906 is the same molecular compound as survodutide. The name change occurred when the WHO assigned an International Nonproprietary Name following Phase 2 trial initiation in 2021.
Survodutide combines GLP-1 receptor agonism (appetite suppression, delayed gastric emptying) with glucagon receptor agonism (hepatic fat oxidation, increased thermogenesis). A dual mechanism absent in semaglutide, tirzepatide, or other incretin-based therapies.
Phase 2 MASH trials showed 12.5% mean weight reduction and up to 52% liver fat reduction at 48 weeks on 2.4mg weekly dosing. Competitive with tirzepatide for weight loss but superior for hepatic fat clearance.
GI side effects (nausea 41%, diarrhea 27%) occurred at rates similar to semaglutide during dose titration, with discontinuation rates of 8–11% in therapeutic dose groups.
The glucagon component raises basal energy expenditure by stimulating brown adipose tissue thermogenesis. An effect that persists even in the absence of caloric restriction, distinguishing it mechanistically from GLP-1-only therapies.

BI 456906 and survodutide refer to the same molecular compound. A first-in-class dual receptor agonist targeting both GLP-1 and glucagon receptors, developed by Boehringer Ingelheim. This isn't a 'me-too' GLP-1 medication following semaglutide or tirzepatide. The glucagon receptor co-activation introduces a metabolic mechanism absent in current GLP-1 therapies: direct hepatic fat oxidation and increased energy expenditure independent of caloric restriction. Phase 2 trials published in The Lancet showed 12.5% mean body weight reduction at 46 weeks on the 4.8mg weekly dose. Competitive with tirzepatide. But with a distinct advantage in liver fat reduction (up to 52% relative reduction) that surpasses what GLP-1 monotherapy achieves.

We've tracked this compound through every clinical phase since its 2019 designation under developmental code BI 456906. Most media coverage treated the INN assignment (survodutide) as a rebrand rather than the standard naming transition. But researchers already knew this mechanism represented a departure from incretin-only therapies.

Is BI 456906 the same compound as survodutide?

Yes. BI 456906 is the developmental research code assigned by Boehringer Ingelheim during preclinical and Phase 1 studies. Survodutide is the International Nonproprietary Name (INN) assigned by the WHO once the compound advanced to Phase 2 trials. The molecular structure, mechanism of action, and pharmacokinetic profile are identical. The name change reflects regulatory nomenclature progression, not a modification to the compound itself.

Direct Answer: Why the Dual-Agonist Mechanism Matters

Most coverage calls survodutide 'another GLP-1 drug'. But that misses the defining characteristic. GLP-1 receptor agonists slow gastric emptying and suppress appetite through hypothalamic satiety signaling. Glucagon receptor agonists increase hepatic fat oxidation, stimulate thermogenesis, and raise basal energy expenditure. Survodutide binds both receptors simultaneously with balanced affinity. Meaning weight loss occurs through appetite suppression AND increased fat burning, not appetite suppression alone. This article covers the exact mechanism that differentiates survodutide from semaglutide and tirzepatide, what the Phase 2 liver fat data actually showed, and why the dual-agonist design introduces trade-offs that single-pathway agonists don't face.

The Dual-Agonist Mechanism: GLP-1 + Glucagon Receptor Co-Activation

Survodutide activates two distinct metabolic pathways through simultaneous receptor binding. The GLP-1 receptor component works identically to semaglutide. It delays gastric emptying (extending the postprandial satiety window by 90–120 minutes) and activates POMC neurons in the hypothalamus that signal fullness. Peak GLP-1 receptor occupancy occurs 12–24 hours post-injection with a half-life of approximately five days, enabling weekly dosing.

The glucagon receptor component introduces the metabolic differentiation. Glucagon receptors in hepatocytes (liver cells) trigger cAMP-mediated lipolysis. The breakdown of stored triglycerides into free fatty acids for oxidation. This occurs independently of caloric deficit. In Phase 2 trials, survodutide reduced liver fat by up to 52% relative to baseline at 48 weeks. A magnitude that GLP-1 monotherapy rarely achieves. Glucagon also stimulates UCP1 (uncoupling protein 1) in brown adipose tissue, increasing non-shivering thermogenesis and raising total daily energy expenditure by an estimated 100–150 calories per day at therapeutic doses.

The balancing act: glucagon receptor activation increases hepatic glucose output, which would normally raise blood sugar. The GLP-1 component counteracts this through enhanced insulin secretion and reduced glucagon secretion from pancreatic alpha cells. In diabetic populations, this balance maintained glycemic control comparable to GLP-1-only therapies. Mean HbA1c reduction of 1.6% at 46 weeks in the MASH-focused cohort.

Clinical Trial Results: Weight Loss, Liver Fat, and Adverse Event Profile

The Phase 2 MASH trial (metabolic dysfunction-associated steatohepatitis) enrolled 293 participants with biopsy-confirmed liver fibrosis. At 48 weeks, the 2.4mg weekly survodutide group achieved 12.5% mean body weight reduction versus 2.3% placebo. The 4.8mg group did not significantly outperform 2.4mg for weight loss but showed marginally greater liver fat reduction (52% vs 47% relative reduction measured by MRI-PDFF).

Liver-specific outcomes: 47% of participants on 2.4mg survodutide achieved MASH resolution without worsening fibrosis, compared to 14% on placebo. Fibrosis improvement by at least one stage occurred in 43% versus 20% placebo. Statistically significant but not yet reaching the two-stage improvement threshold regulators prioritise for accelerated approval.

Adverse events mirrored GLP-1 monotherapy patterns with one exception. Nausea occurred in 41% of survodutide participants (versus 18% placebo) during dose escalation, consistent with semaglutide trials. Diarrhea was more frequent in survodutide groups (27% vs 11%). Likely attributable to glucagon's effects on intestinal motility and bile acid secretion. Discontinuation rates due to GI side effects were 8% in the 2.4mg group and 11% in the 4.8mg group. No pancreatitis cases or medullary thyroid carcinoma events were observed during the 48-week study period.

BI 456906 Same as Survodutide: Comparison

What If: Survodutide Scenarios

What If I See Research Papers Using 'BI 456906' — Is That Outdated?

Not necessarily. Publications submitted before mid-2021 correctly used the developmental code BI 456906 because survodutide had not yet been assigned as the INN. Retrospective analyses and meta-analyses sometimes reference both terms interchangeably when consolidating data across trial phases. If you're cross-referencing clinical trial registries, search both terms. ClinicalTrials.gov entries from 2019–2021 list BI 456906, while entries from 2022 onward use survodutide exclusively.

What If I'm Comparing Survodutide to Tirzepatide — Which Is More Effective?

Direct head-to-head trials don't exist yet, so efficacy comparisons rely on cross-trial inference. Which introduces confounding variables (different populations, different trial durations, different endpoint definitions). Tirzepatide's Phase 3 SURMOUNT-1 trial showed 20.9% mean weight reduction at 72 weeks on the 15mg dose. Survodutide's Phase 2 trial showed 12.5% at 48 weeks on 2.4mg. The shorter duration and lower dose make direct comparison premature. Where survodutide differentiates: liver fat reduction exceeded what tirzepatide achieved in NASH trials, suggesting the glucagon component confers hepatic benefits beyond what GIP/GLP-1 dual agonism provides.

What If Survodutide Increases Blood Sugar Because of the Glucagon Component?

Glucagon receptor activation does increase hepatic glucose output. But the GLP-1 receptor component simultaneously enhances insulin secretion and suppresses endogenous glucagon release from pancreatic alpha cells. In Phase 2 trials, participants with type 2 diabetes on survodutide achieved mean HbA1c reductions of 1.6%. Comparable to semaglutide monotherapy. The dual-agonist design balances the hyperglycemic potential of glucagon activation with the insulin-sensitizing effects of GLP-1, resulting in net glucose-lowering in diabetic populations. Non-diabetic participants showed no clinically significant glucose elevation.

The Unflinching Truth About Dual-Agonist Design

Here's the honest answer: survodutide's dual-agonist mechanism isn't a guaranteed improvement over GLP-1 monotherapy. It's a trade-off. The glucagon component adds hepatic fat oxidation and thermogenesis, which theoretically should produce greater weight loss than GLP-1 alone. But Phase 2 results showed 12.5% reduction at 48 weeks. Impressive, but not categorically superior to semaglutide 2.4mg (14.9% at 68 weeks in STEP-1) or tirzepatide 15mg (20.9% at 72 weeks in SURMOUNT-1). The liver fat benefit is real. 52% relative reduction exceeds what incretin-only therapies achieve. But that advantage matters primarily for MASH populations, not the broader obesity market.

The glucagon component also introduces GI side effects that wouldn't occur with GLP-1 alone. Diarrhea rates (27% vs 18% for semaglutide in comparable trials) reflect glucagon's effects on bile acid secretion and intestinal motility. For patients prioritising weight loss over liver health, the added complexity may not justify the modest efficacy difference. Survodutide's real value proposition is MASH treatment with concurrent weight loss. Not weight loss optimization in metabolically healthy individuals.

Why Research-Grade Peptides Require Precision Synthesis

Dual-agonist peptides like survodutide demand exact amino acid sequencing to maintain balanced receptor affinity. Any deviation in the peptide chain alters binding kinetics, potentially favouring one receptor over the other and destroying the therapeutic ratio. Commercial-grade synthesis uses solid-phase peptide synthesis (SPPS) with HPLC purification to achieve >98% purity, verified by mass spectrometry. Lower-purity preparations (95–97%) contain truncated sequences and deletion peptides that bind receptors with unpredictable affinity, introducing batch-to-batch variability that research applications cannot tolerate.

Our dedication to precision synthesis ensures every peptide batch meets the structural fidelity required for reproducible receptor binding. When you're working with compounds like survodutide peptide or related dual-agonist research tools, purity isn't a marketing claim. It's a functional requirement. A 2% impurity difference translates to measurably different receptor occupancy curves, which cascades into unreliable dose-response data. Researchers comparing metabolic pathways across mazdutide peptide and GLP-1-only analogs need batch consistency. Structural drift between preparations invalidates cross-study comparisons entirely.

The distinction matters most when reconstituting lyophilised peptides. Bacteriostatic water must be pharmaceutical-grade (USP 797 compliant). Distilled water introduces endotoxins that denature peptide structure during storage. Once reconstituted, dual-agonist peptides require refrigeration at 2–8°C and use within 28 days. Temperature excursions above 8°C cause irreversible aggregation. The peptide remains soluble but loses receptor binding affinity because tertiary structure collapses. No visual indicator reveals this degradation; only functional assays detect it.

Survodutide's Phase 3 trials will clarify whether the dual-agonist design delivers clinical superiority over existing therapies. But the mechanism already demonstrates that GLP-1 monotherapy doesn't exhaust the metabolic intervention space. For research applications exploring glucagon's hepatic effects or comparing incretin-based versus glucagon-based satiety pathways, survodutide provides a tool that single-pathway agonists cannot replicate. The compound's journey from developmental code BI 456906 to INN assignment reflects standard pharmaceutical nomenclature. Not a substantive change in what researchers have been studying since 2019.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Yes. BI 456906 is the developmental research code Boehringer Ingelheim used during preclinical and early clinical trials. Survodutide is the International Nonproprietary Name (INN) assigned by the WHO once the compound advanced to Phase 2 trials in 2021. The molecular structure, receptor binding profile, and pharmacokinetics are identical — the name change reflects regulatory nomenclature standards, not a modification to the compound itself.

Survodutide is a dual GLP-1/glucagon receptor agonist, whereas semaglutide is a GLP-1-only agonist and tirzepatide is a GLP-1/GIP dual agonist. The glucagon receptor component in survodutide directly stimulates hepatic fat oxidation and increases thermogenesis through brown adipose tissue activation — mechanisms absent in both semaglutide and tirzepatide. This produces greater liver fat reduction (up to 52% relative reduction) but introduces trade-offs in GI tolerability, particularly increased diarrhea rates.

Phase 2 MASH trials showed 12.5% mean body weight reduction at 48 weeks on the 2.4mg weekly dose, compared to 2.3% with placebo. The 4.8mg dose did not significantly outperform 2.4mg for weight loss but showed marginally greater liver fat reduction. These results are competitive with semaglutide (14.9% at 68 weeks) but fall short of tirzepatide’s highest dose (20.9% at 72 weeks), though direct comparison across different trial designs introduces confounding variables.

Survodutide is currently in Phase 3 trials for both obesity and MASH indications as part of Boehringer Ingelheim’s SYNCHRONIZE program, but it has not yet received regulatory approval for any indication. The dual-agonist mechanism theoretically benefits any population seeking weight loss, but the clinical differentiation versus existing GLP-1 therapies remains unclear. The compound’s strongest competitive advantage appears to be concurrent MASH resolution with weight reduction — not weight loss optimization in metabolically healthy individuals.

Nausea occurred in 41% of participants during dose escalation (versus 18% placebo), consistent with GLP-1 monotherapies. Diarrhea was more frequent with survodutide (27% versus 11% placebo), likely attributable to glucagon’s effects on bile acid secretion and intestinal motility. Discontinuation rates due to GI adverse events were 8% in the 2.4mg group and 11% in the 4.8mg group. No cases of pancreatitis or medullary thyroid carcinoma were observed during the 48-week Phase 2 trial.

Glucagon receptor activation increases hepatic glucose output, but the GLP-1 component simultaneously enhances insulin secretion and suppresses endogenous glucagon release from pancreatic alpha cells. In Phase 2 trials, participants with type 2 diabetes achieved mean HbA1c reductions of 1.6% — comparable to GLP-1 monotherapy. Non-diabetic participants showed no clinically significant glucose elevation. The dual-agonist design balances the hyperglycemic potential of glucagon with the insulin-sensitizing effects of GLP-1.

Lyophilised survodutide powder should be stored at −20°C before reconstitution. Once mixed with bacteriostatic water (USP 797 pharmaceutical-grade only), refrigerate at 2–8°C and use within 28 days. Temperature excursions above 8°C cause irreversible peptide aggregation — the solution remains clear but loses receptor binding affinity because tertiary structure collapses. No visual indicator reveals this degradation; only functional assays detect reduced potency.

GLP-1 monotherapy primarily reduces weight through appetite suppression and delayed gastric emptying, but does not directly stimulate fat oxidation or increase basal energy expenditure. Adding glucagon receptor agonism introduces hepatic lipolysis and thermogenesis — mechanisms that theoretically enhance weight loss and liver fat clearance beyond what incretin hormones achieve alone. Phase 2 data confirmed superior liver fat reduction (52% relative reduction) versus GLP-1-only therapies, validating the mechanistic hypothesis for MASH populations.

Survodutide is not FDA-approved for any indication as of 2026 and remains in Phase 3 clinical development. Research-grade survodutide peptide is available through specialized peptide suppliers for non-human in vitro and in vivo studies under institutional review protocols. These preparations are synthesized to match the clinical compound’s amino acid sequence but are not manufactured under GMP conditions and carry no therapeutic claims. Researchers must verify batch purity (>98% by HPLC) and confirm structural integrity through mass spectrometry before use.

Dual-agonist peptides require precise amino acid sequencing to maintain balanced receptor affinity — any deviation in the peptide chain alters binding kinetics, potentially favouring one receptor over the other and destroying the therapeutic ratio. Solid-phase peptide synthesis (SPPS) must achieve >98% purity with HPLC purification and mass spectrometry verification. Lower-purity preparations (95–97%) contain truncated sequences and deletion peptides that bind receptors with unpredictable affinity, introducing batch-to-batch variability that invalidates dose-response studies.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA